Attached files
| file | filename |
|---|---|
| EX-99.3 - EX-99.3 - VALEANT PHARMACEUTICALS INTERNATIONAL | a56989exv99w3.htm |
| EX-99.2 - EX-99.2 - VALEANT PHARMACEUTICALS INTERNATIONAL | a56989exv99w2.htm |
| EX-99.1 - EX-99.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a56989exv99w1.htm |
| EX-23.1 - EX-23.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a56989exv23w1.htm |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): May 26, 2010
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
| Delaware | 1-11397 | 33-0628076 | ||
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer | ||
| incorporation) | Identification No.) |
One Enterprise
Aliso Viejo, California 92656
(Address of principal executive offices, including zip code)
(949) 461-6000
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Aliso Viejo, California 92656
(Address of principal executive offices, including zip code)
(949) 461-6000
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
| Item 2.01. Completion of Acquisition or Disposition of Assets | ||||||||
| Item 9.01. Financial Statements and Exhibits | ||||||||
| SIGNATURES | ||||||||
| EX-23.1 | ||||||||
| EX-99.1 | ||||||||
| EX-99.2 | ||||||||
| EX-99.3 | ||||||||
Table of Contents
Item 2.01. Completion of Acquisition or Disposition of Assets.
On June 2, 2010, Valeant Pharmaceuticals International (the “Company”) filed a Current Report on
Form 8-K (the “Initial Form 8-K”) to report the completion of our acquisition of Princeton Pharma
Holdings LLC, and its wholly owned operating subsidiary, Aton Pharma, Inc. (collectively, “Aton”).
We are filing this amendment to the Initial Form 8-K to include the financial information required
by Item 9.01.
Item 9.01. Financial Statements and Exhibits.
(a) Financial statements of business acquired
The
audited consolidated financial statements of Princeton Pharma
Holdings LLC and Subsidiary as of and for
the year ended December 31, 2009 are filed as Exhibit 99.1 to this amendment and are incorporated
herein by reference.
The unaudited condensed consolidated financial statements of Princeton Pharma Holdings LLC and
Subsidiary as of March 31, 2010 and for the three month periods ended March 31, 2010 and 2009 are
filed as Exhibit 99.2 to this amendment and are incorporated herein by reference.
(b) Pro Forma Financial Information
The required unaudited pro forma condensed consolidated financial information is attached as
Exhibit 99.3 and is incorporated in its entirety herein by reference.
(c) Exhibits
| Exhibit No. | Description of Exhibit | |
23.1
|
Consent of Independent Auditor. | |
99.1
|
Audited consolidated financial statements of Princeton Pharma Holdings LLC and Subsidiary as of and for the year ended December 31, 2009. | |
99.2
|
Unaudited condensed consolidated financial statements of Princeton Pharma Holdings LLC and Subsidiary as of March 31, 2010 and for the three month periods ended March 31, 2010 and 2009. | |
99.3
|
Unaudited pro forma condensed consolidated financial statements. |
2
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VALEANT PHARMACEUTICALS INTERNATIONAL |
||||
| Date: August 12, 2010 | By: | /s/ PETER J. BLOTT | ||
| Peter J. Blott | ||||
| Executive Vice President and Chief Financial Officer | ||||
3